Alpha Tau Reports 100% Local Disease Control and Favorable Safety in Pancreatic Cancer Trials at DDW 2026
DRTS has more than doubled off its 52-week low of $2.5 on elevated volume (3.1× avg).
Summary
Alpha Tau Medical announced highly positive updated pooled results from two first-in-human pancreatic cancer trials, showing 100% local disease control and a favorable safety profile for its Alpha DaRT therapy, presented at DDW 2026.
Key Events · Product Development and Regulatory · DRTS
-
Positive Clinical Trial Results
Updated pooled data from two first-in-human trials of Alpha DaRT in pancreatic cancer showed a 100% local disease control rate in 19 evaluable patients, with 79% achieving stable disease and 21% partial response.
-
Favorable Safety Profile
Only 8 device-associated adverse events were observed in 7 of 26 subjects (27%), with nearly all resolving within two weeks, demonstrating a strong safety profile for the treatment in heavily pre-treated patients.
-
Presentation at Premier Conference
The results were presented at Digestive Disease Week (DDW) 2026, a premier international gastroenterology conference, marking the first time Alpha DaRT clinical results were selected for oral presentation at such an event.
Analysis · DRTS · Industrial Applications And Services
This filing provides significant positive clinical data for Alpha Tau's Alpha DaRT therapy in pancreatic cancer, a notoriously difficult-to-treat indication. The achievement of 100% local disease control in evaluable patients, coupled with a favorable safety profile, represents a major de-risking event for the technology and strengthens its commercial potential. The presentation at a premier international gastroenterology conference (DDW 2026) further enhances the credibility and visibility of these results, potentially attracting investor interest and paving the way for further clinical development and regulatory approvals.
At the time of this filing, DRTS was trading at $8.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $751.6M. The 52-week trading range was $2.50 to $8.80. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.